Search

everythinglearnresearchcommunity

for

Search:↓

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Targeting FGF5 could help treat prostate cancer.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

CT scans can find serious prostate cancer even when PSA levels are low.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Finasteride may help prevent prostate cancer.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.